GlassScriptPhysician profile
Aubrey A King
NPI 1669577896
$2,785.83
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $366 · 2021: $918 · 2022: $1,094 · 2023: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $596.36 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $504.47 | 2019-2022 | |
| Alkermes, INC. | $447.84 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $379.34 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $199.70 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $144.33 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $100.63 | 2022-2023 | Uzedy |
| Supernus Pharmaceuticals, INC. | $97.03 | 2022-2023 | Qelbree |
| Indivior INC. | $79.42 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $75.67 | 2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $53.26 | 2022 | |
| Allergan, INC. | $43.89 | 2019-2020 | |
| Abbvie INC. | $19.37 | 2021 | |
| Eisai INC. | $15.73 | 2022 | |
| Bausch Health US, LLC | $14.90 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.